Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab concentration-guided switching after adalimumab failure in rheumatoid arthritis
NL-OMON24414Recruiting
- Sponsor
- Reade Rheumatology Research Institute
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Reade Rheumatology Research Institute. Primary endpoint: Mean time-weighted DAS28-CRP at 28 weeks. Started Jul 2020; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON24414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24414.